LEAP THERAPEUTICS, INC.
CAMBRIDGE, MA · Founded 2011 · CIK 0001509745 · Biotech · Public
Monoclonal antibody (DKN-01) targeting DKK1 protein for cancer treatment
leaptx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $105M
- 3 Form D · Mar 2023
- 43 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 16
- 2 granted · 14 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2010201220142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $9,930,400 | |
| Private capital raised | Form D · SEC | $18,000,001 | |
| Private capital raised | Form D · SEC | $77,219,193 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2821 | Acadia Pharmaceuticals | — | $107M |
| 2822 | Neurogene Inc. | — | $106M |
| 2823 | Ovid Therapeutics | — | $106M |
| 2824 | LEAP THERAPEUTICS, INC. | — | $105M |
| 2825 | CENTRILLION BIOSCIENCES, INC. | — | — |
| 2826 | Adaptimmune | — | $104M |
| 2827 | Civitas Therapeutics | — | $104M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- James CavanaughDirector
- Thomas DietzDirector
- Christine GranfieldExecutive Officer
- Augustine LawlorDirector · Executive Officer
- William LiDirector
- John LittlechildDirector
- Joseph LoscalzoDirector
- Patricia MartinDirector
- Nissim MashiachDirector
- Christopher MirabelliDirector · Executive Officer
- Mark O'MahonyExecutive Officer
- Douglas OnsiDirector · Executive Officer
- Christian RichardDirector
- Richard SchilskyDirector
- Cynthia SirardExecutive Officer
Patents
- Combination Therapyapplication
- Use Of Beta-catenin As A Biomarker For Treating Cancers Using ANTI-DKK-1 Antibodygranted
- Methods Of Treating Cancer Using DKK-1 Inhibitorsapplication
- Use Of DKK-1 Inhibitors For Treating Cancerapplication
- Use Of Beta-catenin As A Biomarker For Treating Cancers Using ANTI-DKK-1 Antibodygranted
- Combination Therapyapplication
- Methods Of Treating Cancer Using DKK-1 Inhibitorsapplication
- Methods Of Treating Cancer Using DKK-1 Inhibitorsapplication
- Methods Of Treating Cancer Using DKK-1 Inhibitorsapplication
- Use Of Beta-catenin As A Biomarker For Treating Cancers Using ANTI-DKK-1 Antibodyapplication
- Combination Therapyapplication
- Use of Beta-Catenin as a Biomarker for Treating Cancers Using Anti-DKK-1 Antibodyapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.